Nothing Special   »   [go: up one dir, main page]

Stringer et al., 2019 - Google Patents

A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma

Stringer et al., 2019

View HTML
Document ID
3844853202653356862
Author
Stringer B
Day B
D’Souza R
Jamieson P
Ensbey K
Bruce Z
Lim Y
Goasdoué K
Offenhäuser C
Akgül S
Allan S
Robertson T
Lucas P
Tollesson G
Campbell S
Winter C
Do H
Dobrovic A
Inglis P
Jeffree R
Johns T
Boyd A
Publication year
Publication venue
Scientific reports

External Links

Snippet

Low-passage, serum-free cell lines cultured from patient tumour tissue are the gold-standard for preclinical studies and cellular investigations of glioblastoma (GBM) biology, yet entrenched, poorly-representative cell line models are still widely used, compromising the …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Similar Documents

Publication Publication Date Title
Stringer et al. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma
Esposito et al. Bone vascular niche E-selectin induces mesenchymal–epithelial transition and Wnt activation in cancer cells to promote bone metastasis
Inoue et al. Spliceosomal disruption of the non-canonical BAF complex in cancer
Iacobucci et al. Genomic subtyping and therapeutic targeting of acute erythroleukemia
Alonso-Curbelo et al. A gene–environment-induced epigenetic program initiates tumorigenesis
Wu et al. YAP drives fate conversion and chemoresistance of small cell lung cancer
Lewandowski et al. The Firre locus produces a trans-acting RNA molecule that functions in hematopoiesis
Seki et al. Recurrent SPI1 (PU. 1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia
Tammela et al. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma
Lee et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins
Siira et al. Concerted regulation of mitochondrial and nuclear non‐coding RNA s by a dual‐targeted RN ase Z
Lazzari et al. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma
Chaudhury et al. Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias
Whissell et al. The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression
Frattini et al. The integrated landscape of driver genomic alterations in glioblastoma
Zhang et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis
Topka et al. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia
Venkatraman et al. Maternal imprinting at the H19–Igf2 locus maintains adult haematopoietic stem cell quiescence
Arnes et al. Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma
Osorio et al. Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling
Smeenk et al. Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer in leukemia
Kobayashi et al. Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors
Astolfi et al. Targeted deep sequencing uncovers cryptic kit mutations in Kit/Pdgfra/Sdh/Ras-p wild-type gist
Ren et al. Activation of TLR7 increases CCND3 expression via the downregulation of miR-15b in B cells of systemic lupus erythematosus
Wallis et al. Neurofibromin (NF1) genetic variant structure–function analyses using a full‐length mouse cDNA